Across TCGA pan-cancer cohorts, RPL6P2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of RPL6P2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPL6P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL6P2 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

KIRC, THCA, and BRCA are the cancer types where RPL6P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL6P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	II,III,IV	+0.064	<.001	7	view →
THCA	Female	III,IV	−0.080	.010	4	view →
BRCA	All	III,IV	−0.141	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RPL6P2 RNA expression & survival · all RPL6P2 data types